secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000886163-23-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q1 revenue $44M beats prior year; raises FY2023 EPS guidance to $4.60-$4.75
--------------------------------------------------------------------------------

- Total revenue $44.0M, up 21% from $36.5M in Q1 2022; net income $43.6M vs loss $12.9M.
- Raised FY2023 guidance: royalties $78-82M (prev $74-78M); diluted EPS $4.60-4.75 (prev $3.30-3.45).
- Royalty revenue $17.2M (+28% YoY) driven by Kyprolis and Pelican platform; core Captisol sales $10.6M (+71%).
- Sold 3.2M shares of Viking Therapeutics for $43M net proceeds; holds 3.6M VKTX shares as of Mar 31, 2023.
- Travere's FILSPARI approved for IgA nephropathy in Feb; Phase 3 FSGS study missed primary endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/0000886163-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000024/lgnd-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer